Is donepezil therapy associated with reduced mortality in nursing home residents with dementia?

American Journal Geriatric Pharmacotherapy

Volumn 3, Issue 1, 2005, Pages 1-7

  Gasper, Mason C ^a   Ott, Brian R ^a,c   Lapane, Kate L ^b  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

Author keywords

Alzheimer's disease; Dementia; Donepezil; Mortality

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

AGED; ARTICLE; CANCER; CHRONIC OBSTRUCTIVE LUNG DISEASE; COGNITION; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DISEASE SEVERITY; DOSE RESPONSE; DRUG USE; FEMALE; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MORTALITY; NURSING HOME; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; SENILE DEMENTIA; SOCIOECONOMICS; SURVIVAL RATE; SURVIVAL TIME;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DATABASES, FACTUAL; DEMENTIA; FEMALE; HUMANS; INDANS; MALE; NOOTROPIC AGENTS; NURSING HOMES; PIPERIDINES; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TACRINE;

EID: 23744442900     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2005.02.001     Document Type: Article

References (32)

1. Doody R.S. Stevens J.C. Beck C. et al. Practice parameter: Management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology 56 2001 1154-1166
2. Raskind M.A. Peskind E.R. Truyen L. et al. The cognitive benefits of galantamine are sustained for at least 36 months: A long-term extension trial Arch Neurol 61 2004 252-256
3. Doody R.S. Geldmacher D.S. Gordon B. Donepezil et al. for the Study Group Open-label multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease Arch Neurol 58 2001 427-433
4. Farlow M. Potkin S. Koumaras B. et al. Analysis of outcome in retrieved dropout patients in rivastigmine vs placebo, 26-week, Alzheimer disease trial Arch Neurol 60 2003 843-848
5. Krishnan K.R. Charles H.C. Doraiswamy P.M. et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease Am J Psychiatry 160 2003 2003-2011
6. Wessler I. Kilbinger H. Bittinger F. et al. The nonneuronal cholinergic system in humans: Expression, function, and pathophysiology Life Sci 72 2003 2055-2061
7. Ott B.R. Lapane K.L. Tacrine therapy is associated with reduced mortality in nursing home residents with dementia J Am Geriatr Soc 50 2002 35-40
8. Hill J.W. Futterman R. Duttagupta S. et al. Alzheimer's disease and related dementias increase costs of comorbidities in managed Medicare Neurology 58 2002 62-70
9. Tariot P.N. Cummings J.L. Katz I.R. et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezll in patients with Alzheimer's disease in the nursing home setting J Am Geriatr Soc 49 2001 1590-1599
10. Abstract 1 Katzman R. Epidemiology of Alzheimer's disease Neurobiol Aging 21 Suppl 1 2000 S1
11. Courtney C. Farrell D. Gray R. et al. for the AD2000 Collaborative Group Long-term donepezll treatment in 565 patients with Alzheimer's disease (AD2000): Randomised double-blind trial Lancet 363 2004 2105-2115
12. Knopman D. Schneider L. Davis K. et al. Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality, Tacrine Study Group Neurology 47 1996 166-177
13. Lopez O.L. Becker J.T. Wisniewski S. et al. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease J Neurol Neurosurg Psychiatry 72 2002 310-314
14. Geldmacher D.S. Provenzano G. McRae T. et al. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease J Am Geriatr Soc 51 2003 937-944
15. Pedone C. Lapant K.L. Mor V. Bernabei R. Donepezil use in US nursing homes Aging Clin Exp Res 16 2004 60-67
16. Gifford D.R. Lapant K.L. Gambassi G. et al. for the SAGE Study Group Tacrine use in nursing homes: Implications for prescribing new cholinesterase inhibitors Neurology 52 1999 238-244
17. Bernabei R. Gambassi G. The SAGE database: Introducing functional outcomes in geriatric pharmacoepidemiology J Am Geriatr Soc 46 1998 251-252
18. Bernabei R. Gambassi G. Lapane K. et al. for the SAGE Study Group Characteristics of the SAGE database: A new resource for research on outcomes in long-term care J Gerontol A Biol Sci Med Sci 54 1999 M25-M33
19. Birks J.S. Melzer D. Donepezil for mild and moderate Alzheimer's disease Cochrane Database Syst Rev 2 2000 CD001190
20. Mor V. Branco K. Fleishman J. et al. The structure of social engagement among nursing home residents J Gerontol B Psychol Sci Soc Sci 50 1995 P1-P8
21. Morris J.N. Fries B.E. Mehr D.R. et al. MDS Cognitive Performance Scale J Gerontol 49 1994 M174-M182
22. Hartmaier S.L. Sloane P.D. Guess H.A. Koch G.G. The MDS Cognition Scale: A valid instrument for identifying and staging nursing home residents with dementia using the minimum data set J Am Geriatr Soc 42 1994 1173-1179
23. Hartmaier S.L. Sloane P.D. Guess H.A. et al. Validation of the Minimum Data Set Cognitive Performance Scale: Agreement with the Mini-Mental State Examination J Gerontol A Biol Sci Med Sci 50 1995 M128-M133
24. Gambassi G. Landi F. Peng L. et al. for the SAGE Study Group Validity of diagnostic and drug data in standardized nursing home resident assessments: Potential for geriatric pharmacoepidemiology Med Care 36 1998 167-179
25. Abstract McKeith I. Del Ser T. Anand R. et al. Rivastigmine provides symptomatic benefit in dementia with Lewy bodies: Findings from a placebo-controlled international multicenter study Neurology 54 2000 A450
26. Aarsland D. Laake K. Larsen J.P. Janvin C. Donepezil for cognitive impairment in Parkinson's disease: A randomized controlled study J Neurol Neurosurg Psychiatry 72 2002 708-712 [published correction appears in J Neurol Neurosurg Psychiatry. 2002;73:354]
27. Wilkinson D. Doody R. Helme R. et al. Donepezil in vascular dementia: A randomized, placebo-controlled study Neurology 61 2003 479-486
28. Lopez O.L. Becker J.T. Klunk W. et al. Research tvaluation and diagnosis of possible Alzheimer's disease over the last two decades: II Neurology 55 2000 1863-1869
29. Erkinjuntti T. Kurz A. Gauthier S. et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial Lancet 359 2002 1283-1290
30. Geldmacher D.S. Provenzano G. McRae T. Icni J.R. Mortality in donepezil-treated patients J Am Geriatr Soc 52 2004 1413 Letter
31. Post S.G. Quality of life: Issues in the cultural perception of dementia in; The Moral Challenge of Alzheianer Disease 1995 Johns Hopkins University Press Baltimore, Md 76-77
32. Lopez O.L. Wisniewski S.R. Becker J.T. et al. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease Arch Neurol 56 1999 1266-1272